Park-VISX FDA Trial

• treatments for the reduction/elimination of nearsightedness (0.0 to -6.o d sphere) and astigmatism (-0.75 to -4.0 d of cylinder).

• uncorrected visual acuity:

  • 1600 eyes with 3 years of follow-up
  • 20/40-94%
  • 20/20-58%